What is the primary purpose of the joint generic sourcing entity formed by Cardinal Health and CVS Caremark?

The joint generic sourcing entity is established to combine the purchasing power of Cardinal Health and CVS Caremark to negotiate more favorable pricing for generic pharmaceuticals. This aims to increase competitiveness and potentially lower costs for both companies and their customers.

When was this joint venture announced?

The announcement was made on December 10, 2013, through a joint news release filed with the SEC.

What is the expected impact on Cardinal Health's business?

This strategic partnership is expected to strengthen Cardinal Health's position in the pharmaceutical supply chain, particularly in the generics market, by improving its ability to secure competitive pricing and potentially enhance its profit margins on generic drug sales.

Are there any financial details provided in this filing regarding the joint venture?

This particular 8-K filing (Item 7.01) primarily serves as a Regulation FD disclosure and includes the joint news release. It does not contain detailed financial projections or terms of the joint venture; further information would likely be found in subsequent filings or company communications.

CAH 8-K: Regulation FD — Dec 10, 2013

Summary

Cardinal Health Inc. (CAH) announced on December 10, 2013, a significant strategic development: the formation of a joint generic sourcing entity in the United States with CVS Caremark Corporation. This partnership aims to leverage the combined purchasing power of both companies to secure more competitive pricing for generic pharmaceuticals. The news was disseminated through a joint press release, included as an exhibit to the 8-K filing.

Key Highlights

1Cardinal Health is forming a new joint generic sourcing entity in the United States.
2The entity is a collaboration with CVS Caremark Corporation.
3The primary goal of this joint venture is to enhance generic pharmaceutical sourcing capabilities.
4This move is expected to improve the competitiveness of generic drug pricing for both companies.
5The announcement was made via a joint news release filed with the SEC.
6This action signals a strategic effort to gain greater control over supply chain costs and pricing power in the generics market.

CARDINAL HEALTH INC 8-K Report, Regulation FD Disclosure (Dec 10, 2013)

Summary

Key Highlights

Frequently Asked Questions